Florida Gov. DeSantis hints at suing FDA over stalled Canadian drug import plan

Zachary Brennan

Senior Editor

While pledging to save “hundreds of millions of dollars” by allowing cheaper Canadian imports of “the same drugs,” Florida Gov. Ron DeSantis on Friday hinted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Florida Gov. DeSantis hints at suing FDA over stalled Canadian drug import plan

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Flori­da Gov. De­San­tis hints at su­ing FDA over stalled Cana­di­an drug im­port plan

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Florida Gov. DeSantis hints at suing FDA over stalled Canadian drug import plan

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development